Early Plasma Reduces Mortality in Traumatic Intracranial Hemorrhage

Temporal Dynamics of Resuscitation in Traumatic Brain Injury

Traumatic brain injury remains a leading cause of mortality and long-term disability, with intracranial hemorrhage frequently requiring aggressive resuscitation to mitigate secondary neurological damage. Clinical management of these patients necessitates a multidisciplinary approach focused on the rapid correction of coagulopathy and the maintenance of physiological homeostasis [1]. Current consensus guidelines emphasize the importance of organized response plans and the early use of blood products, yet the specific timing and ideal ratios for components like plasma remain subjects of ongoing clinical debate [2]. Systemic complications, such as accidental hypothermia, further complicate the clinical picture by significantly increasing the risk of in-hospital mortality in the setting of head trauma [3]. While advanced diagnostic tools like viscoelastic haemostatic assays (point-of-care tests that measure the physical properties of a clot as it forms to guide transfusion) have been integrated into many trauma centers, their ability to improve survival over standard protocols is still being evaluated [4]. A recent multicenter analysis now provides specific data on how the timing of plasma transfusion directly influences 30-day mortality in this population.

Analysis of a High-Acuity Trauma Cohort

The researchers conducted a retrospective analysis using data from the American College of Surgeons Trauma Quality Improvement Program database, focusing on adult trauma patients aged 18 years or older who presented between 2020 and 2021. Because traumatic intracranial hemorrhage is a major driver of traumatic brain injury-related mortality, the study specifically targeted patients with this diagnosis who received plasma-based resuscitation within 4 hours of arrival at the emergency department. To ensure the cohort reflected acute management outcomes and to minimize confounding variables, the authors excluded patients with prehospital cardiac arrest, those on anticoagulant therapy, individuals with nonsurvivable head injuries, and interfacility transfers. A total of 6,183 patients met these rigorous criteria and were included in the final analysis, providing a robust sample size for evaluating the temporal effects of plasma administration. The study population was predominantly male (73%) with a median age of 41 years. Clinical characteristics indicated a high-acuity cohort, as evidenced by a median injury severity score of 34 (a summary score of traumatic injuries across multiple body regions where scores over 15 typically indicate major trauma). The neurological burden was similarly high, with a median head Abbreviated Injury Scale score of 4, a measure of the severity of injury to the head that indicates a severe injury level. Blunt mechanisms accounted for 88% of the injuries observed in this group. Within this high-risk population, the overall in-hospital 30-day mortality rate was 45%, highlighting the critical nature of the cases analyzed and the potential impact of resuscitation timing on survival outcomes.

The Critical Thirty-Minute Window

The researchers initiated the study with the hypothesis that earlier plasma transfusion improves outcomes and that a specific temporal threshold exists after which survival benefits begin to diminish. To evaluate this, they assessed the primary outcome of 30-day mortality using a multivariable Royston-Parmar flexible parametric regression model (a statistical method used to model survival data over time while accounting for non-linear effects and multiple variables). The analysis demonstrated that patients who received plasma transfusion had a 45% lower hazard of death at 30 days compared with those who had not yet received plasma at similar time points (adjusted hazard ratio, 0.55; 95% confidence interval: 0.33 to 0.92; p = 0.02). This finding underscores the substantial survival advantage associated with plasma administration during the acute phase of traumatic intracranial hemorrhage, suggesting that plasma may play a vital role in stabilizing the intracranial environment and preventing the expansion of hematomas. The timing of administration proved to be a critical determinant of efficacy, as predicted survival declined sharply within the first 30 minutes of arrival. Specifically, the data revealed a 5% absolute decrease in survival for every 10-minute delay in plasma transfusion during this initial half-hour window. Beyond the 30-minute mark, the survival benefit of plasma transfusion plateaued, suggesting a diminishing return on late-stage administration. Furthermore, the researchers observed that the risk of neurosurgical interventions increased when plasma was administered beyond the 30-minute threshold, indicating that delayed resuscitation may correlate with a greater need for invasive surgical management. For the practicing clinician, these results suggest that the first 30 minutes of emergency department arrival represent a critical therapeutic window where rapid plasma administration can most significantly influence patient survival and potentially reduce the need for subsequent neurosurgical procedures.

References

1. Rossaint R, Bouillon B, Černý V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Critical Care. 2016. doi:10.1186/s13054-016-1265-x

2. Dzik S, Blajchman MA, Fergusson D, et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panel. Critical Care. 2011. doi:10.1186/cc10498

3. Rösli D, Schnüriger B, Candinas D, Haltmeier T. The Impact of Accidental Hypothermia on Mortality in Trauma Patients Overall and Patients with Traumatic Brain Injury Specifically: A Systematic Review and Meta‐Analysis. World Journal of Surgery. 2020. doi:10.1007/s00268-020-05750-5

4. Baksaas‐Aasen K, Gall L, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Medicine. 2020. doi:10.1007/s00134-020-06266-1